|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 465.34 USD | -1.68% |
|
+4.54% | +97.76% |
| 12-03 | Alnylam Pharmaceuticals Announces Changes to Board of Directors | CI |
| 12-03 | Alnylam Pharmaceuticals announces changes to board of directors | RE |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -17.85 | -12.56 | -13.65 | -4.78 | -2.74 | |||||
Return on Total Capital | -23.8 | -16.46 | -18.77 | -7.17 | -4.19 | |||||
Return On Equity % | -69.92 | -106.31 | -526.14 | 232.4 | 362.29 | |||||
Return on Common Equity | -69.92 | -106.31 | -526.14 | 232.4 | 362.29 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 84.16 | 83.4 | 83.73 | 83.02 | 85.62 | |||||
SG&A Margin | 133.55 | 83.16 | 74.29 | 43.52 | 43.39 | |||||
EBITDA Margin % | -161.04 | -78.3 | -71.39 | -12.48 | -5.35 | |||||
EBITA Margin % | -168.09 | -83.93 | -75.68 | -15.43 | -7.87 | |||||
EBIT Margin % | -168.09 | -83.93 | -75.68 | -15.43 | -7.87 | |||||
Income From Continuing Operations Margin % | -174.15 | -101.01 | -109.04 | -24.08 | -12.37 | |||||
Net Income Margin % | -174.15 | -101.01 | -109.04 | -24.08 | -12.37 | |||||
Net Avail. For Common Margin % | -174.15 | -101.01 | -109.04 | -24.08 | -12.37 | |||||
Normalized Net Income Margin | -115.35 | -67.2 | -61.28 | -14.24 | -10.41 | |||||
Levered Free Cash Flow Margin | -157.68 | 11.5 | -38.87 | 8.01 | 8.8 | |||||
Unlevered Free Cash Flow Margin | -146.97 | 22.09 | -29.48 | 12.16 | 12.75 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.17 | 0.24 | 0.29 | 0.5 | 0.56 | |||||
Fixed Assets Turnover | 0.73 | 1.17 | 1.41 | 2.5 | 3.17 | |||||
Receivables Turnover (Average Receivables) | 6.78 | 5.61 | 4.75 | 6.46 | 6.13 | |||||
Inventory Turnover (Average Inventory) | 1.19 | 1.73 | 1.57 | 2.85 | 3.86 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 4.47 | 4.04 | 3.51 | 3.08 | 2.78 | |||||
Quick Ratio | 4.23 | 3.79 | 3.16 | 2.86 | 2.61 | |||||
Operating Cash Flow to Current Liabilities | -1.05 | -0.92 | -0.7 | 0.11 | -0.01 | |||||
Days Sales Outstanding (Average Receivables) | 54 | 65.06 | 76.79 | 56.47 | 59.67 | |||||
Days Outstanding Inventory (Average Inventory) | 308.43 | 210.39 | 232.78 | 128.23 | 94.88 | |||||
Average Days Payable Outstanding | 192.34 | 151.24 | 148.06 | 103.6 | 84.22 | |||||
Cash Conversion Cycle (Average Days) | 170.09 | 124.21 | 161.51 | 81.1 | 70.33 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 156.73 | 371.59 | -1.65K | -1.22K | 4.09K | |||||
Total Debt / Total Capital | 61.05 | 78.8 | 106.45 | 108.96 | 97.61 | |||||
LT Debt/Equity | 151.79 | 358.39 | -1.6K | -1.17K | 3.86K | |||||
Long-Term Debt / Total Capital | 59.12 | 76 | 103.1 | 105.04 | 92.1 | |||||
Total Liabilities / Total Assets | 70.17 | 83.86 | 104.46 | 105.76 | 98.42 | |||||
EBIT / Interest Expense | -9.8 | -4.95 | -5.03 | -2.33 | -1.25 | |||||
EBITDA / Interest Expense | -8.03 | -3.74 | -4.64 | -1.33 | -0.38 | |||||
(EBITDA - Capex) / Interest Expense | -8.86 | -4.27 | -5.1 | -1.85 | -0.63 | |||||
Total Debt / EBITDA | -2.35 | -4.09 | -3.61 | -16.61 | -50.36 | |||||
Net Debt / EBITDA | 0.42 | 0.47 | -0.58 | -1.51 | -0.9 | |||||
Total Debt / (EBITDA - Capex) | -2.13 | -3.58 | -3.29 | -11.99 | -30.91 | |||||
Net Debt / (EBITDA - Capex) | 0.38 | 0.41 | -0.53 | -1.09 | -0.55 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 124.28 | 71.31 | 22.88 | 76.23 | 22.97 | |||||
Gross Profit, 1 Yr. Growth % | 113.06 | 69.75 | 23.36 | 74.75 | 26.81 | |||||
EBITDA, 1 Yr. Growth % | -13.94 | -16.7 | 12.03 | -69.2 | -47.3 | |||||
EBITA, 1 Yr. Growth % | -11.82 | -14.46 | 10.78 | -64.06 | -37.31 | |||||
EBIT, 1 Yr. Growth % | -11.82 | -14.46 | 10.78 | -64.06 | -37.31 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -3.14 | -0.64 | 32.64 | -61.08 | -36.82 | |||||
Net Income, 1 Yr. Growth % | -3.14 | -0.64 | 32.64 | -61.08 | -36.82 | |||||
Normalized Net Income, 1 Yr. Growth % | 1.46 | -0.2 | 12.03 | -59.04 | -10.14 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -7.96 | -3.54 | 29.11 | -62.1 | -38.18 | |||||
Accounts Receivable, 1 Yr. Growth % | 138.11 | 93.89 | 19.84 | 37.75 | 23.65 | |||||
Inventory, 1 Yr. Growth % | 33.46 | 14.84 | 49.33 | -30.87 | -11.93 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 9.3 | 3.84 | 0.68 | -1.74 | -4.39 | |||||
Total Assets, 1 Yr. Growth % | 42.25 | 6.93 | -2.66 | 7.99 | 10.71 | |||||
Tangible Book Value, 1 Yr. Growth % | -29.36 | -42.12 | -126.9 | 39.45 | -130.41 | |||||
Common Equity, 1 Yr. Growth % | -29.36 | -42.12 | -126.9 | 39.45 | -130.41 | |||||
Cash From Operations, 1 Yr. Growth % | 120.87 | 4.35 | -15.65 | -119.24 | -107.98 | |||||
Capital Expenditures, 1 Yr. Growth % | -49.8 | 8.54 | -5.65 | -13.67 | -44.9 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 86.88 | -112.5 | -515.25 | -136.34 | 91.09 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 74.18 | -125.75 | -263.96 | -172.7 | 59.8 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 156.5 | 96.01 | 45.08 | 47.16 | 47.21 | |||||
Gross Profit, 2 Yr. CAGR % | 138.2 | 90.18 | 44.71 | 46.82 | 48.86 | |||||
EBITDA, 2 Yr. CAGR % | -0.36 | -15.34 | -3.4 | -41.26 | -59.71 | |||||
EBITA, 2 Yr. CAGR % | 0.84 | -13.15 | -2.65 | -36.9 | -52.53 | |||||
EBIT, 2 Yr. CAGR % | 0.84 | -13.15 | -2.65 | -36.9 | -52.53 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 6.16 | -1.9 | 14.8 | -28.15 | -50.41 | |||||
Net Income, 2 Yr. CAGR % | 6.16 | -1.9 | 14.8 | -28.15 | -50.41 | |||||
Normalized Net Income, 2 Yr. CAGR % | 9.1 | 0.63 | 5.74 | -32.26 | -39.33 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -0.7 | -5.78 | 11.59 | -30.03 | -51.58 | |||||
Accounts Receivable, 2 Yr. CAGR % | 133.65 | 114.87 | 52.43 | 28.48 | 30.51 | |||||
Inventory, 2 Yr. CAGR % | 76.76 | 23.8 | 30.95 | 1.6 | -21.98 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 48.44 | 6.54 | 2.25 | -0.54 | -3.07 | |||||
Total Assets, 2 Yr. CAGR % | 47.09 | 23.33 | 2.02 | 2.53 | 9.34 | |||||
Tangible Book Value, 2 Yr. CAGR % | -11.65 | -36.06 | -60.54 | -38.75 | -34.88 | |||||
Common Equity, 2 Yr. CAGR % | -11.65 | -36.06 | -60.54 | -38.75 | -34.88 | |||||
Cash From Operations, 2 Yr. CAGR % | 4.55 | 51.81 | -6.18 | -59.71 | -87.61 | |||||
Capital Expenditures, 2 Yr. CAGR % | -25.53 | -26.18 | 1.2 | -9.75 | -31.03 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 28.56 | -51.67 | -27.96 | 22.83 | -33.27 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 24.11 | -33.03 | -35.03 | 9.17 | -9.11 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 76.32 | 124.21 | 67.75 | 54.8 | 38.61 | |||||
Gross Profit, 3 Yr. CAGR % | 66.47 | 112.77 | 64.62 | 54.1 | 39.82 | |||||
EBITDA, 3 Yr. CAGR % | 17.58 | -6.14 | -7.05 | -34.01 | -43.35 | |||||
EBITA, 3 Yr. CAGR % | 18.32 | -4.54 | -5.81 | -30.16 | -37.04 | |||||
EBIT, 3 Yr. CAGR % | 18.32 | -4.54 | -5.81 | -30.16 | -37.04 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 20.47 | 3.85 | 8.48 | -19.95 | -31.16 | |||||
Net Income, 3 Yr. CAGR % | 20.47 | 3.85 | 8.48 | -19.95 | -31.16 | |||||
Normalized Net Income, 3 Yr. CAGR % | 22.99 | 5.91 | 4.3 | -22.92 | -25.57 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 11.25 | -1.66 | 4.65 | -22.13 | -32.86 | |||||
Accounts Receivable, 3 Yr. CAGR % | 44.42 | 119.56 | 76.87 | 47.37 | 26.85 | |||||
Inventory, 3 Yr. CAGR % | - | 53.1 | 31.78 | 5.83 | -3.13 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 57.19 | 31.77 | 4.55 | 0.9 | -1.84 | |||||
Total Assets, 3 Yr. CAGR % | 19.54 | 32.26 | 13.98 | 3.98 | 5.19 | |||||
Tangible Book Value, 3 Yr. CAGR % | -16.83 | -23.27 | -52.09 | -39.9 | -51.5 | |||||
Common Equity, 3 Yr. CAGR % | -16.83 | -23.27 | -52.09 | -39.9 | -51.5 | |||||
Cash From Operations, 3 Yr. CAGR % | 17.12 | 4.48 | 24.81 | -44.67 | -76.52 | |||||
Capital Expenditures, 3 Yr. CAGR % | -12.27 | -15.57 | -19.89 | -4.02 | -23.44 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 33.24 | -40.89 | -1.02 | -42.66 | 26.78 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 30.15 | -26.53 | -9.74 | -32.55 | 15.39 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 64.35 | 78.07 | 63.09 | 89.45 | 59.21 | |||||
Gross Profit, 5 Yr. CAGR % | 58.78 | 71.72 | 57.4 | 83.42 | 58.13 | |||||
EBITDA, 5 Yr. CAGR % | 23.44 | 10.06 | 8.69 | -22.18 | -33.47 | |||||
EBITA, 5 Yr. CAGR % | 22.85 | 10.79 | 9.44 | -19.11 | -28.39 | |||||
EBIT, 5 Yr. CAGR % | 22.85 | 10.79 | 9.44 | -19.11 | -28.39 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 24.23 | 15.77 | 18.17 | -10.38 | -20.68 | |||||
Net Income, 5 Yr. CAGR % | 24.23 | 15.77 | 18.17 | -10.38 | -20.68 | |||||
Normalized Net Income, 5 Yr. CAGR % | 25.68 | 16.83 | 15.77 | -11.43 | -16.03 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 16.67 | 8.49 | 11.39 | -14.18 | -23.11 | |||||
Accounts Receivable, 5 Yr. CAGR % | 65.3 | 53.46 | 47.57 | 77.2 | 56.62 | |||||
Inventory, 5 Yr. CAGR % | - | - | - | 29.94 | 6.86 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 90.98 | 44.97 | 32.35 | 17.75 | 1.43 | |||||
Total Assets, 5 Yr. CAGR % | 19.7 | 23.6 | 12.2 | 19.45 | 12.1 | |||||
Tangible Book Value, 5 Yr. CAGR % | -4.28 | -8.56 | -38.28 | -29.88 | -45.83 | |||||
Common Equity, 5 Yr. CAGR % | -4.28 | -8.56 | -38.28 | -29.88 | -45.83 | |||||
Cash From Operations, 5 Yr. CAGR % | 26.59 | 15.84 | 7.17 | -28.63 | -50.46 | |||||
Capital Expenditures, 5 Yr. CAGR % | 40.29 | 3.42 | -7.11 | -13.29 | -24.55 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 40.78 | -12.41 | 4.18 | -20.8 | -13.8 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 38.81 | -0.2 | -1.43 | -13.92 | -7.18 |
- Stock Market
- Equities
- ALNY Stock
- Financials Alnylam Pharmaceuticals, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















